Neutra Corp prioritizes Neutra Life Sciences growth through Q3 and Q4 2026

The OTC-listed company said it is concentrating resources on sponsor and CRO outreach, conference attendance and a debt-settlement-related agreement with VIVIS Corporation.

CRO

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.